New Psychoactive Substances: Which Biological Matrix Is the Best for Clinical Toxicology Screening?

被引:6
|
作者
Wagmann, Lea [1 ]
Jacobs, Cathy M. [1 ]
Meyer, Markus R. [1 ]
机构
[1] Saarland Univ, Ctr Mol Signaling PZMS, Inst Expt & Clin Pharmacol & Toxicol, Dept Expt & Clin Toxicol, Kirrberger Str Bldg 46, D-66421 Homburg, Germany
关键词
new psychoactive substances; drugs of abuse; mass spectrometry; clinical toxicology; RESOLUTION MASS-SPECTROMETRY; PACKED SORBENT; EXHALED BREATH; ORAL FLUID; AMPHETAMINES; URINE; DRUGS; ABUSE; BLOOD; MICROEXTRACTION;
D O I
10.1097/FTD.0000000000000974
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
Background: Every year, more new psychoactive substances (NPSs) emerge in the market of the drugs of abuse. NPSs belong to various chemical classes, such as synthetic cannabinoids, phenethylamines, opioids, and benzodiazepines. The detection of NPSs intake using different types of biological matrices is challenging for clinical toxicologists because of their structural diversity and the lack of information on their toxicokinetics, including their metabolic fate. Methods: PubMed-listed articles reporting mass spectrometry-based bioanalytical approaches for NPSs detection published during the past 5 years were identified and discussed. Furthermore, the pros and cons of using common biological matrices in clinical toxicology (CT) settings to screen for NPSs are highlighted in this review article. Results: Twenty-six articles presenting multianalyte screening methods for use in the field of CT were considered. The advantages and disadvantages of different biological matrices are discussed with a particular view of the different analytical tasks in CT, especially emergency toxicology. Finally, an outlook introduces the emerging trends in biosamples used in CT, such as the exhaled breath. Conclusions: Blood and urine represent the most common biological matrices used in a CT setting; however, reports concerning NPSs detection in alternative matrices are also available. Noteworthy, the selection of the biological matrix must depend on the clinician's enquiry because the individual advantages and disadvantages must be considered.
引用
收藏
页码:599 / 605
页数:7
相关论文
共 50 条
  • [21] The prevalence of new psychoactive substances in biological material - a three-year review of casework in Poland
    Adamowicz, Piotr
    Gieron, Joanna
    Gil, Dominika
    Lechowicz, Wojciech
    Skulska, Agnieszka
    Tokarczyk, Bogdan
    DRUG TESTING AND ANALYSIS, 2016, 8 (01) : 64 - 71
  • [22] Neurotoxicity screening of new psychoactive substances (NPS): Effects on neuronal activity in rat cortical cultures using microelectrode arrays (MEA)
    Zwartsen, Anne
    Hondebrink, Laura
    Westerink, Remco H. S.
    NEUROTOXICOLOGY, 2018, 66 : 87 - 97
  • [23] Wide-scope target and suspect screening methodologies to investigate the occurrence of new psychoactive substances in influent wastewater from Athens
    Diamanti, Konstantina
    Aalizadeh, Reza
    Alygizakis, Nikiforos
    Galani, Aikaterini
    Mardal, Marie
    Thomaidis, Nikolaos S.
    SCIENCE OF THE TOTAL ENVIRONMENT, 2019, 685 : 1058 - 1065
  • [24] Simultaneous LC-MS/MS screening for multiple phenethylamine-type conventional drugs and new psychoactive substances in urine
    Fan, Shu-Yu
    Zang, Chi-Zong
    Shih, Po-Han
    Ko, Ya-Chun
    Hsu, Ya-Hui
    Lin, Mei-Chih
    Tseng, Su-Hsiang
    Wang, Der-Yuan
    FORENSIC SCIENCE INTERNATIONAL, 2021, 325
  • [25] Rapid Screening of New Psychoactive Substances Using pDART-QqQ-MS
    Hsu, Wei-Hsin
    Cheng, Kai-Wen
    Feng, Tzu-Hsuan
    Chen, Ju-Yu
    Chen, Guan-Yuan
    Chen, Lian-Yu
    Weng, Te-, I
    Hsu, Cheng-Chih
    JOURNAL OF THE AMERICAN SOCIETY FOR MASS SPECTROMETRY, 2024, 35 (06) : 1370 - 1376
  • [26] New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues
    Schifano, Fabrizio
    Napoletano, Flavia
    Chiappini, Stefania
    Orsolini, Laura
    Guirguis, Amira
    Corkery, John Martin
    Bonaccorso, Stefania
    Ricciardi, Angelo
    Scherbaum, Norbert
    Vento, Alessandro
    CURRENT ADDICTION REPORTS, 2019, 6 (02) : 140 - 152
  • [27] New Psychoactive Substances (NPS), Psychedelic Experiences and Dissociation: Clinical and Clinical Pharmacological Issues
    Fabrizio Schifano
    Flavia Napoletano
    Stefania Chiappini
    Laura Orsolini
    Amira Guirguis
    John Martin Corkery
    Stefania Bonaccorso
    Angelo Ricciardi
    Norbert Scherbaum
    Alessandro Vento
    Current Addiction Reports, 2019, 6 : 140 - 152
  • [28] Biochip array technology for new psychoactive substances detection in biological samples: Evaluation of the specificity of the Randox Evidence Investigator®
    Deville, Marine
    Bailly, Ronald
    Gauthier, Nicolas
    Pitti, Pauline
    Wachtelaer, Audrey
    Charlier, Corinne
    ANNALS OF CLINICAL BIOCHEMISTRY, 2022, 59 (05) : 357 - 362
  • [29] Simple and rapid screening procedure for 143 new psychoactive substances by liquid chromatography-tandem mass spectrometry
    Adamowicz, Piotr
    Tokarczyk, Bogdan
    DRUG TESTING AND ANALYSIS, 2016, 8 (07) : 652 - 667
  • [30] Screening new psychoactive substances in urban wastewater using high resolution mass spectrometry
    Iria González-Mariño
    Emma Gracia-Lor
    Renzo Bagnati
    Claudia P. B. Martins
    Ettore Zuccato
    Sara Castiglioni
    Analytical and Bioanalytical Chemistry, 2016, 408 : 4297 - 4309